Vanda Pharmaceuticals Inc.
VNDADrugs in Pipeline
20
Phase 3 Programs
12
Upcoming Catalysts
14
Next Catalyst
Mar 15, 2026
8dMarket Overview
Stock performance and key metrics
16 upcoming, 3 past
Trichostatin A Phase 2 Results Expected
Primary completion for Trichostatin A trial (NCT07065773) in Onychomycosis of Toenail
SourceVCA-894A Phase 2 Results Expected
Primary completion for VCA-894A trial (NCT07223632) in Charcot Marie Tooth Disease (CMT)
Source14 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Tasimelteon Oral Suspension
Insomnia Disorder
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Autism Spectrum Disorder
Ziprasidone
Schizophrenia
Tasimelteon
Sleep Wake Disorders
Milsaperidone
Major Depressive Disorder (MDD)
iloperidone
Schizophrenia
Open Label Tradipitant
Idiopathic Gastroparesis
Imsidolimab high dose
Generalized Pustular Psoriasis
VQW-765
Performance Anxiety
20 mg VEC-162
Insomnia
VEC-162 20 mg
Primary Insomnia
Tradipitant
Motion Sickness
Imsidolimab
Acne Vulgaris
VLY-686 (Tradipitant)
Gastroparesis
VSJ-110
Dry Eye
Trichostatin A
Onychomycosis of Toenail
VLY-686
Treatment-resistant Pruritus Associated With Atopic Dermatitis
VSF-173
Excessive Somnolence
VCA-894A
Charcot Marie Tooth Disease (CMT)
VEC-162
Circadian Rhythm Sleep Disorders
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tasimelteon Oral Suspension | Phase 3 | Insomnia Disorder | - | - |
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Phase 3 | Autism Spectrum Disorder | - | - |
Ziprasidone | Phase 3 | Schizophrenia | - | - |
Tasimelteon | Phase 3 | Sleep Wake Disorders | - | - |
Milsaperidone | Phase 3 | Major Depressive Disorder (MDD) | - | - |
iloperidone | Phase 3 | Schizophrenia | - | - |
Open Label Tradipitant | Phase 3 | Idiopathic Gastroparesis | - | - |
Imsidolimab high dose | Phase 3 | Generalized Pustular Psoriasis | - | - |
VQW-765 | Phase 3 | Performance Anxiety | - | - |
20 mg VEC-162 | Phase 3 | Insomnia | - | - |
VEC-162 20 mg | Phase 3 | Primary Insomnia | - | - |
Tradipitant | Phase 3 | Motion Sickness | - | - |
Imsidolimab | Phase 2 | Acne Vulgaris | - | - |
VLY-686 (Tradipitant) | Phase 2 | Gastroparesis | - | - |
VSJ-110 | Phase 2 | Dry Eye | - | - |
Trichostatin A | Phase 2 | Onychomycosis of Toenail | - | - |
VLY-686 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | - | - |
VSF-173 | Phase 2 | Excessive Somnolence | - | - |
VCA-894A | Phase 2 | Charcot Marie Tooth Disease (CMT) | - | - |
VEC-162 | Phase 2 | Circadian Rhythm Sleep Disorders | - | - |